Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) are increasingly prescribed for diabetic and nondiabetic patients with and without heart failure (HF) or renal insufficiency [1]. SGLT2i reduce blood glucose levels by inhibiting renal glucose reabsorption in the proximal convoluted tubule. Adverse effects of SGLT2i comprise genito-urinary infections, ketoacidosis and volume depletion [2]. There are concerns that SGLT2i may also affect the skeletal muscle, either in form of myopathy or by promoting sarcopenia [3–6].
